All were met by positive peer review, and ESTRO awarded research and development lead dosimetrist, Hayley Chesham, with an award for best RTT poster for the first phase in her work analysing reduced PTV margins for prostate IMRT with daily online IGRT. Using data from a pool of patients across three GenesisCare centres – in South Downs, Southampton and Elstree - the study looked at prostate patients being treated with 74Gy in 37 fractions using IMRT with daily IGRT. This is the standard dose and duration of radiation treatment for prostate cancer according to the National Institute of Health and Care Excellence (NICE) guidance.
In order to investigate if PTV (planning target volume) could be reduced from the standard 7mm margin if using daily imaging, Hayley analysed data comparing the delivery to the prostate and surrounding area with what would have been treated had imaging only taken place once at the start of the treatment.
Hayley, who is based at GenesisCare’s Elstree Cancer Centre in Hertfordshire, said: “It is early days and this was just a taster using the initial findings from the pilot of eleven patients. It confirms there could be scope to reduce planning target volume margins to 5mm for prostate IMRT with daily IGRT. This would further reduce the risk of side effects without reducing the effectiveness of the treatment. It’s very exciting, and we’re looking forward to completing the research over the next few months.”
Over 1,800 abstracts were submitted to ESTRO33, of which over 500 were displayed as posters on at the event. Each was independently scored by four members of the Scientific Advisory Group, chaired by Michelle Leech, head of discipline of radiation therapy at the School of Medicine in Dublin, Ireland.
Michelle said: “The jury took into account the academic content as well as poster layout, creativity and visualisation. They also rated the information’s relevance to the profession and its value to radiation therapy technologists in their daily practice. Hayley added: “I was surprised but really pleased to have won. Dr Ariyaratne and I have worked hard on the project, and a lot of work still needs to be done, but it’s nice to have our initial results well received by the European radiotherapy community.”
GenesisCare is committed to providing all patients with the most highly targeted and effective radiotherapy available, and offers daily image guided, intensity modulated radiotherapy as standard.
Chief medical officer, Prof Karol Sikora, said: “We know that combining IMRT and daily IGRT provides the best outcomes for patients. But not many cancer centres in the UK offer daily imaged guided treatment, and there is very little research into this in the UK so this was one area we were keen to focus on when we set up our research unit.
“I’m pleased the various presentations and posters from our team were well received at ESTRO, and am delighted that Hayley’s dedicated work was recognised with the announcement she’d won the best poster.”